Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. AMZN
7. USO
8. LMT
9. TLT
10. BETR

Go back to Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab
Amgen Inc (NASDAQ: AMGN) Delayed: 379.35 +3.00 (0.80%)
Previous Close $376.35    52 Week High $176.85 
Open $379.15    52 Week Low $133.64 
Day High $382.49    P/E 57.13 
Day Low $376.08    EPS $6.64 
Volume 1,377,282